• Hyalgan Fidia (Hyaluronic acid) 20mg/2ml syringe

Expiration date: 07/2025

Release form, composition and packaging 

Solution for intra-articular introduction colorless, transparent, viscous.

1 ml 1 syringe contains:

sodium hyaluronate 10 mg 20 mg

Auxiliary substances: sodium chloride 17 mg disodium hydrogen phosphate dodecahydrate - 1.2 mg, sodium dihydrogen phosphate dihydrate - 0.1 mg, water d/and - to 2 ml.

2 ml - colourless glass syringes (1) - packaging sells contoured (1) - packs of cardboard.

2 ml - colourless glass syringes (5) - packaging sells contoured (1) - packs of cardboard.

Clinico-pharmacological group: Drug that stimulates the regeneration of cartilage tissue

Pharmaco-therapeutic group: tissue Regeneration stimulator

Testimony

  • for the relief of pain and improvement of mobility of synovial joints, in osteoarthritis and post-traumatic changes;
  • as adjuvant in orthopaedic surgery.

The dosage regimen

The drug is intended for intra-articular injection.

In the knee and hip joints, the drug is administered in a dose of 20 mg 1 time per week (contents of 1 vial 20 mg/2 ml or filled syringe). The course consists of 3-5 injections.

Rules of administration

Must observe the rules of aseptic and antiseptic during the procedure.

Before the introduction of Hyalgan Phidias should remove effusion from the joint capsule. The drug should be administered accurately into the joint cavity by standard methods, given the anatomical features. To remove the effusion and drug administration you can use the same needle, once introduced prior to aspiration. The syringe with the drug to be attached to the needle, released from the syringe with aspirated fluid. To confirm the finding of the needle in the joint cavity should be available to aspirate the synovial fluid before the slow introduction of the drug. The introduction of the drug into the joint cavity should be stopped with the appearance of pain during injection.

Avoid getting air into the syringe with the drug.

Remaining in the syringe, the drug is not storable.

Side effects

Local reactions: possible mild transient pain, swelling, increase in the content of the exudate in the joint cavity, fever and redness at the injection site. These reactions are transient in nature and usually disappear after 24 hours (if you have any of these symptoms, it is recommended to unload the affected joint and apply ice).

Allergic reactions: in rare cases - itching, rash, urticaria, anaphylactic reactions.

Contraindications

  • severe liver disease;
  • infection or damage to the skin at the injection site;
  • hypersensitivity to the drug component;
  • hypersensitivity to avian proteins.

Application of pregnancy and breastfeeding

It should appoint a drug during pregnancy and lactation (breastfeeding) in the absence of clinical data on use in this category of patients.

Application for violations of liver function

The drug is contraindicated in severe liver disease.

The children

In the absence of clinical data for use in Pediatrics the drug should not be administered to children.

Special instructions

During the first 2 days after the procedure it is recommended not to overload the joint, especially avoid prolonged activity.

When receiving the aspiration fluid before the introduction of the drug should conduct appropriate studies to exclude bacterial etiology of arthritis.

Use in Pediatrics

In the absence of clinical data for use in Pediatrics the drug should not be administered to children.

Effects on ability to drive vehicles and management mechanisms

Hyalgan Pheidias does not affect the ability to drive vehicles and other potentially hazardous activities, require high concentration and psychomotor speed reactions.

Overdose

Currently, cases of overdose are not observed.

Drug interactions

Hyalgan Pheidias should not be administered concurrently with other drugs for intra-articular introduction due to the lack of sufficient clinical experience.

You should not use disinfectants containing Quaternary ammonium salts because hyaluronic acid is precipitated in the presence of these substances.

Conditions of supply of pharmacies

A drug dispensed by prescription.

Terms and conditions storage

The drug should be stored out of the reach of children, protected from light place at temperature not exceeding 25°C; do not freeze. Shelf life is 3 years when stored in original packaging.

You should not use the drug Hyalgan Pheidias with damaged or opened packaging.

Hyalgan
Fidia
(Hyaluronic
acid)
20mg/2ml
syringe

  • $154.00